Intellia Therapeutics Share Price Today
(NASDAQ: NTLA)

Name: Intellia Therapeutics Share Price Today (NASDAQ: NTLA) - Intellia Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Intellia Therapeutics share price is $7.23 & ₹617.91 as on 18 Apr 2025, 2.30 'hrs' IST

$7.23

▲

0.37

(5.39%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Intellia Therapeutics share price in Dollar and Rupees. Guide to invest in Intellia Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Intellia Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Intellia Therapeutics share price movements

Today's Low: $6.88
Today's High: $7.28
$7.23
4.84%
Downside
Day's Volatility :5.43%
Upside
0.62%
52 Weeks Low: $5.90
52 Weeks High: $28.18
$7.23
18.4%
Downside
52 Weeks Volatility :79.06%
Upside
74.34%

Intellia Therapeutics (NTLA) Returns

Period	Intellia Therapeutics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-27.26%	-2.8%	0.0%
6 Months	-65.02%	-11.0%	0.0%
1 Year	-66.48%	-1.9%	0.0%
3 Years	-85.69%	-1.5%	-12.9%

Intellia Therapeutics (NTLA) Key Statistics

in dollars & INR

Previous Close	$6.86
Open	$6.85
Today's High	$7.275
Today's Low	$6.88
Market Capitalization	$748.4M
Today's Volume	$2.9M
52 Week High	$28.18
52 Week Low	$5.9
Revenue TTM	$57.9M
EBITDA	$-524.0M
Earnings Per Share (EPS)	$-5.25
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-54.01%

How to invest in Intellia Therapeutics Stock (NTLA) from India?

It is very easy for Indian residents to invest directly in Intellia Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Intellia Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Intellia Therapeutics or NTLA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Intellia Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Intellia Therapeutics shares which would translate to 0.118 fractional shares of Intellia Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Intellia Therapeutics, in just a few clicks!

Returns in Intellia Therapeutics (NTLA) for Indian investors in Rupees

The Intellia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Intellia Therapeutics investment value today

Current value as on today

₹35,860

Returns

₹64,140

(-64.14%)

Returns from Intellia Therapeutics Stock

₹66,481 (-66.48%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Intellia Therapeutics (NTLA)

71.43%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Investment in Intellia Therapeutics Shares from India has grown by 71.43% over the past 30 days, indicating increased transactional activity.

-17%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Intellia Therapeutics Stock from India on INDmoney has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Intellia Therapeutics

ARK Investment Management LLC
12.11%
BlackRock Inc
10.49%
Vanguard Group Inc
9.84%
State Street Corp
5.03%
Morgan Stanley - Brokerage Accounts
3.68%
Regeneron Pharmaceuticals Inc
3.58%

Analyst Recommendation on Intellia Therapeutics

Rating

Trend

Buy

79%Buy

20%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Intellia Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Intellia Therapeutics Stock (NTLA)

What analysts predicted

Upside of 504.32%

Target:

$43.69

Current:

$7.23

Insights on Intellia Therapeutics Stock (Ticker Symbol: NTLA)

Price Movement
In the last 7 days, NTLA stock has moved down by -7.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 6.95M → 12.87M (in $), with an average increase of 26.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -146.97M → -128.89M (in $), with an average increase of 6.8% per quarter
NTLA vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 144.3%
NTLA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 116.9%
Price to Sales
ForNTLA every $1 of sales, investors are willing to pay $12.3, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

Intellia Therapeutics Technicals Summary

Sell

Neutral

Buy

Intellia Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Intellia Therapeutics (NTLA) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Intellia Therapeutics Inc.	-21.15%	-65.02%	-66.48%	-85.69%	-49.51%
Regeneron Pharmaceuticals, Inc.	-17.1%	-41.85%	-37.2%	-21.74%	-0.85%
Beone Medicines Ltd	-13.12%	5.03%	78.34%	40.23%	43.44%
Vertex Pharmaceuticals Incorporated	-4.76%	2.3%	24.05%	71.43%	78.99%
Alnylam Pharmaceuticals, Inc.	-9.09%	-19.67%	62.43%	39.66%	61.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Intellia Therapeutics Inc.	NA	NA	-0.1	-4.77	-0.54	-0.27	NA	8.55
Regeneron Pharmaceuticals, Inc.	14.68	14.68	0.9	41.18	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	17.96	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.81	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Intellia Therapeutics Inc.	Buy	$748.4M	-49.51%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.5B	-0.85%	14.68	31.07%
Beone Medicines Ltd	NA	$26.9B	43.44%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$125.7B	78.99%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	61.91%	NA	-12.37%

Intellia Therapeutics Dividend announcements

Intellia Therapeutics Earnings
Intellia Therapeutics’s price-to-earnings ratio stands at None

About Intellia Therapeutics

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organization	Intellia Therapeutics
Employees	403
CEO	Dr. Laura Sepp-Lorenzino Ph.D.
Industry	Health Technology

Management People of Intellia Therapeutics

Name	Title
Dr. John M. Leonard M.D.	President, CEO & Director
Dr. Laura Sepp-Lorenzino Ph.D.	Special Advisor to the Chief Executive Officer
Dr. David Lebwohl M.D.	Executive VP & Chief Medical Officer
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder
Dr. Andrew May Ph.D.	Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Derrick J. Rossi Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Rodolphe Barrangou M.B.A., Ph.D.	Founder & Member of Scientific Advisor Board
Prof. Luciano Marraffini Ph.D.	Founder & Member of Scientific Advisor Board
Mr. Erik J. Sontheimer Ph.D.	Founder & Member of Scientific Advisor Board

Important FAQs about investing in NTLA Stock from India :

What is Intellia Therapeutics share price today?

Intellia Therapeutics share price today stands at $7.23, Open: $6.85 ; Previous Close: $6.86 ; High: $7.28 ; Low: $6.88 ; 52 Week High: $28.18 ; 52 Week Low: $5.90.

The stock opens at $6.85, after a previous close of $6.86. The stock reached a daily high of $7.28 and a low of $6.88, with a 52-week high of $28.18 and a 52-week low of $5.90.

Can Indians buy Intellia Therapeutics shares?

Yes, Indians can invest in the Intellia Therapeutics (NTLA) from India.

With INDmoney, you can buy Intellia Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Intellia Therapeutics at zero transaction cost.

How can I buy Intellia Therapeutics shares from India?

It is very easy to buy Intellia Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Intellia Therapeutics (NTLA) be purchased?

Yes, you can buy fractional shares of Intellia Therapeutics with INDmoney app.

What are the documents required to start investing in Intellia Therapeutics stocks?

To start investing in Intellia Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.